StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) stock

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)

Close on Nov 17, 2026Market cap $28.91MP/E –Yield –

Aytu BioPharma total assets

Total assets on the balance sheet at the end of each period.

Aytu BioPharma's total assets was $105.01M at Jun 30, 2026. For fiscal 2026 it was $105.01M, down 15.4% from the year before. Over ten years it grew 15.7% a year on average. The highest annual figure on record is $265.67M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2026Jun 30, 2026$105.01M-15.4%
FY2025Jun 30, 2025$124.18M+5.2%
FY2024Jun 30, 2024$118.10M-13.5%
FY2023Jun 30, 2023$136.46M-0.8%
FY2022Jun 30, 2022$137.62M-48.2%
FY2021Jun 30, 2021$265.67M+73.3%
FY2020Jun 30, 2020$153.29M+341.5%
FY2019Jun 30, 2019$34.72M+64.9%
FY2018Jun 30, 2018$21.06M+40.4%
FY2017Jun 30, 2017$15.00M-38.4%
FY2016Jun 30, 2016$24.34M+33.9%
FY2015Jun 30, 2015$18.19M+187979.2%
FY2013Aug 31, 2013$9.67K-23.5%
FY2012Aug 31, 2012$12.65K-44.6%
FY2011Aug 31, 2011$22.84K–

Quarterly total assets

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026$105.01M-15.4%
Q3 FY2026CQ1 2026Mar 31, 2026$111.69M-10.1%
Q2 FY2026CQ4 2025Dec 31, 2025$122.00M+5.0%
Q1 FY2026CQ3 2025Sep 30, 2025$124.99M+7.9%
Q4 FY2025CQ2 2025Jun 30, 2025$124.18M+5.2%
Q3 FY2025CQ1 2025Mar 31, 2025$124.20M-3.6%
Q2 FY2025CQ4 2024Dec 31, 2024$116.23M-11.4%
Q1 FY2025CQ3 2024Sep 30, 2024$115.83M-12.8%
Q4 FY2024CQ2 2024Jun 30, 2024$118.10M-13.5%
Q3 FY2024CQ1 2024Mar 31, 2024$128.86M-12.5%
Q2 FY2024CQ4 2023Dec 31, 2023$131.25M-7.2%
Q1 FY2024CQ3 2023Sep 30, 2023$132.89M-11.4%
Q4 FY2023CQ2 2023Jun 30, 2023$136.46M-0.8%
Q3 FY2023CQ1 2023Mar 31, 2023$147.22M-12.8%
Q2 FY2023CQ4 2022Dec 31, 2022$141.44M-36.8%
Q1 FY2023CQ3 2022Sep 30, 2022$150.00M-34.1%
Q4 FY2022CQ2 2022Jun 30, 2022$137.62M-48.2%
Q3 FY2022CQ1 2022Mar 31, 2022$168.83M-37.8%
Q2 FY2022CQ4 2021Dec 31, 2021$223.82M+34.2%
Q1 FY2022CQ3 2021Sep 30, 2021$227.73M+61.2%
Q4 FY2021CQ2 2021Jun 30, 2021$265.67M+73.3%
Q3 FY2021CQ1 2021Mar 31, 2021$271.56M+70.8%
Q2 FY2021CQ4 2020Dec 31, 2020$166.74M+123.9%
Q1 FY2021CQ3 2020Sep 30, 2020$141.27M+355.4%
Q4 FY2020CQ2 2020Jun 30, 2020$153.29M+341.5%
Q3 FY2020CQ1 2020Mar 31, 2020$158.95M+314.6%
Q2 FY2020CQ4 2019Dec 31, 2019$74.48M+75.7%
Q1 FY2020CQ3 2019Sep 30, 2019$31.02M+72.5%
Q4 FY2019CQ2 2019Jun 30, 2019$34.72M+64.9%
Q3 FY2019CQ1 2019Mar 31, 2019$38.34M+64.0%
Q2 FY2019CQ4 2018Dec 31, 2018$42.40M+124.8%
Q1 FY2019CQ3 2018Sep 30, 2018$17.98M-15.3%
Q4 FY2018CQ2 2018Jun 30, 2018$21.06M+40.4%
Q3 FY2018CQ1 2018Mar 31, 2018$23.37M+46.9%
Q2 FY2018CQ4 2017Dec 31, 2017$18.86M-12.3%
Q1 FY2018CQ3 2017Sep 30, 2017$21.25M+41.6%
Q4 FY2017CQ2 2017Jun 30, 2017$15.00M–
Q3 FY2017CQ1 2017Mar 31, 2017$15.92M–
Q2 FY2017CQ4 2016Dec 31, 2016$21.51M–
Q1 FY2017CQ3 2016Sep 30, 2016$15.00M–

More Aytu BioPharma figures

See a number that looks wrong?